Long Ideas - With the majority of statins now generic, pharmaceutical companies are on the hunt for the next blockbuster cardiovascular drug to replace what was once a … Continue Reading
Read NowMost Popular - Medivation (MDVN) has made a rapid come-back since investors exited en masse in mid-June as the company’s closest development-stage competitor was bought by J&J (JNJ). … Continue Reading
Read NowLong Ideas - We last covered Synageva BioPharma (GEVA) in early January, arguing that the company faced fundamental risks that made its valuation a concern moving forward. But … Continue Reading
Read NowMost Popular - Shares of TG Therapeutics (TGTX) had a rough end to last week and a worse beginning to this week. But it was that weakness that … Continue Reading
Read NowMost Popular - A study published yesterday in PLOS Biology offers a damning assessment of recent IPO PTC Therapeutics’ (PTCT) lead candidate ataluren. PTC began trading on the Nasdaq last … Continue Reading
Read NowMost Popular - Isis Pharmaceuticals (ISIS) revealed impressive numbers from its Phase II trial of ISIS-APOCIIIRx in patients with high triglycerides and type 2 diabetes yesterday at the American Diabetes Association … Continue Reading
Read NowMost Popular - The FDA accepted Durect’s (DRRX) New Drug Application for Posidur on Thursday, causing shares to gap up and continue higher through the day. Analysts expect … Continue Reading
Read Now